Masimo (MASI)
(Real Time Quote from BATS)
$111.31 USD
-2.96 (-2.59%)
Updated Sep 6, 2024 03:53 PM ET
After-Market: $111.67 +0.36 (0.32%) 4:12 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.31 USD
-2.96 (-2.59%)
Updated Sep 6, 2024 03:53 PM ET
After-Market: $111.67 +0.36 (0.32%) 4:12 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Zacks News
IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?
by Zacks Equity Research
The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos
by Zacks Equity Research
Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Masimo (MASI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) Latest Watch to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.
Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.
Masimo (MASI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 13.45% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 26.47% and 0.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 3.92% and 2.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Here's Why You Should Buy ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
NuVasive (NUVA) to Expand in APAC With New Experience Center
by Zacks Equity Research
NuVasive's (NUVA) Singapore Experience Center will complement the flagship Experience Centers in San Diego and the New York metropolitan area.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
Intuitive (ISRG) New Lung Biopsy Imaging Technology Gets FDA Nod
by Zacks Equity Research
The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.
Catalent (CTLT) Expands Packaging Capabilities at Japan Facility
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.